Good News! SBK Becomes the First Domestic Company to Have Chloral Hydrate Syrup Included in the 2024 National Reimbursement Drug List

Chengdu Shibeikang Biomedical Technology Co., Ltd. (the Company) is excited to announce that its self-developed Chloral Hydrate Syrup has been officially included in the 2024 National Reimbursement Drug List, following evaluation and review by the relevant authorities. This achievement marks a major milestone in the Company’s efforts to improve access to innovative drugs, providing a new boost to its long-term development.

The Chloral Hydrate Syrup, developed independently by SBK, is primarily used for sedation and hypnosis in children before examinations or procedures. With its stable quality and ease of storage, the syrup significantly enhances medication safety and patient compliance. As the first pediatric-specific Chloral Hydrate Syrup formulation approved in China, it addresses the pressing need for pediatric medications in the market.

The inclusion of Chloral Hydrate Syrup in the reimbursement list not only highlights its clinical efficacy but also recognizes its role in meeting important clinical needs. With this achievement, SBK has reached a significant milestone in novel drug R&D and enhancing drug accessibility, making it easier and more affordable for patients to access high-quality treatments.

Looking ahead, SBK will continue to drive the accessibility of this drug, ensuring that more patients can benefit from affordable treatment options. The Company remains committed to technological innovation, patient-focused R&D investment, and the development of novel therapies to improve patient outcomes. SBK is dedicated to advancing global healthcare and addressing urgent public health challenges.